評論
打印
And, furthermore, when skeletal muscle is injured, that's what causes chemokines -- these signals saying,
此外，當骨骼肌受傷時，會導致趨化因子——這些信號說：
"Cancer, you can come to me," the "go signs" for the tumors -- it causes them to highly express these chemokines.
“癌癥，你可以來找我，”腫瘤的綠燈通行信號，這會導致這些趨化因子的高效表達。
So, there's so much interplay here. I mean, there are so many possibilities for why tumors don't go to skeletal muscle.
因此，這里有太多的相互作用我的意思是，有如此多的可能性，可以解釋為什么腫瘤不出現在骨骼肌中。
But it seems like by investigating, by attacking cancer, by searching where cancer is not,
通過調查，攻擊癌細胞還有搜索不會發生癌癥的部位都預示一定有什么，
there has got to be something -- there's got to be something -- that's making this tissue resistant to tumors.
一定存在某種特性使這種組織可以抗腫瘤。
And can we utilize -- can we take this property, this compound, this receptor, whatever it is that's controlling these anti-tumor properties and apply it to cancer therapy in general?
那么我們能否利用-我們能否把這種特性 用這種化合物，這種受體，這種控制抗腫瘤特性的因子，來治療癌癥？
Now, one thing that kind of ties the resistance of skeletal muscle to cancer -- to the cancer as a repair response gone out of control in the body --
現在，有一件事與骨骼肌的抗癌性有點關系，這是對由身體的修復反應引起的癌癥而言。
is that skeletal muscle has a factor in it called "MyoD."
它就是骨骼肌中叫做MyoD的因子。
And what MyoD essentially does is, it causes cells to differentiate into muscle cells.
MyoD所做的就是，導致細胞分化成肌細胞。
So this compound, MyoD, has been tested on a lot of different cell types and been shown to actually convert this variety of cell types into skeletal muscle cells.
因此，這種物質，MyoD，已在很多不同的細胞類型上做過測試，結果表明，它可以將多種類型的細胞轉化為骨骼肌細胞。
So, is it possible that the tumor cells are going to the skeletal muscle tissue,
因此，有可能腫瘤細胞已經進入骨骼肌肉組織，
but once in contact inside the skeletal muscle tissue, MyoD acts upon these tumor cells and causes them to become skeletal muscle cells?
但一旦與骨骼肌內的組織接觸， MyoD的作用于這些腫瘤細胞，使它們成為骨骼肌細胞？
Maybe tumor cells are being disguised as skeletal muscle cells, and this is why it seems as if it is so rare.
腫瘤細胞可能被偽裝成骨骼肌細胞，這就是為什么它在骨骼肌中如此罕見。
